InsiderTrades.com logo
Steven D. Rubin net worth and biography
  • Phone
  • Email
  • Website

Steven Rubin Biography and Net Worth

Executive Vice President, Administration of OPKO Health

Mr. Rubin has served as Executive Vice President, Administration at OPKO since May 2007 and as a director since February 2007. Previously, Mr. Rubin served as the Senior Vice President, General Counsel and Secretary of IVAX from August 2001 until September 2006.

Mr. Rubin currently serves on the board of directors of Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates; Non-Invasive Monitoring Systems, Inc., a medical device company; Cocrystal Pharma, Inc., a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses; ChromaDex Corp., a science-based integrated nutraceutical company devoted to improving the way people age; Neovasc, Inc. a company developing and marketing medical specialty vascular devices, and Red Violet, Inc., leading analytics and information solutions provider.

Mr. Rubin previously served as a director of Castle Brands, Inc., Dreams, Inc., Safestitch Medical, Inc., Cogent, Inc., PROLOR Biotech, Inc., BioCardia, Inc., and VBI Vaccines, Inc.

What is Steven D. Rubin's net worth?

The estimated net worth of Steven D. Rubin is at least $234,289.08 as of March 19th, 2025. Mr. Rubin owns 141,138 shares of OPKO Health stock worth more than $234,289 as of March 31st. This net worth estimate does not reflect any other assets that Mr. Rubin may own. Additionally, Mr. Rubin receives a salary of $1,220,000.00 as Executive Vice President, Administration at OPKO Health. Learn More about Steven D. Rubin's net worth.

How old is Steven D. Rubin?

Mr. Rubin is currently 64 years old. There are 7 older executives and no younger executives at OPKO Health. The oldest executive at OPKO Health is Dr. Phillip Frost Ph.D., Chairman & CEO, who is 88 years old. Learn More on Steven D. Rubin's age.

What is Steven D. Rubin's salary?

As the Executive Vice President, Administration of OPKO Health, Inc., Mr. Rubin earns $1,220,000.00 per year. There are 3 executives that earn more than Mr. Rubin. The highest earning executive at OPKO Health is Dr. Phillip Frost Ph.D., Chairman & CEO, who commands a salary of $1,450,000.00 per year. Learn More on Steven D. Rubin's salary.

How do I contact Steven D. Rubin?

The corporate mailing address for Mr. Rubin and other OPKO Health executives is 4400 BISCAYNE BLVD., MIAMI FL, 33137. OPKO Health can also be reached via phone at (305) 575-4100 and via email at mmiller@lhai.com. Learn More on Steven D. Rubin's contact information.

Has Steven D. Rubin been buying or selling shares of OPKO Health?

Steven D. Rubin has not been actively trading shares of OPKO Health in the last ninety days. Most recently, on Friday, January 5th, Steven D. Rubin bought 10,000 shares of OPKO Health stock. The stock was acquired at an average cost of $0.87 per share, with a total value of $8,700.00. Following the completion of the transaction, the vice president now directly owns 6,187,732 shares of the company's stock, valued at $5,383,326.84. Learn More on Steven D. Rubin's trading history.

Who are OPKO Health's active insiders?

OPKO Health's insider roster includes Jon Cohen (SVP), Phillip Frost (CEO), Richard Krasno (Director), Richard Pfenniger, Jr. (Director), and Steven Rubin (Executive Vice President, Administration). Learn More on OPKO Health's active insiders.

Are insiders buying or selling shares of OPKO Health?

In the last twelve months, OPKO Health insiders bought shares 14 times. They purchased a total of 2,683,223 shares worth more than $4,111,852.32. In the last twelve months, insiders at the biotechnology company sold shares 15 times. They sold a total of 736,644 shares worth more than $23,874,134.15. The most recent insider tranaction occured on March, 28th when CEO Phillip Md Et Al Frost bought 150,000 shares worth more than $255,000.00. Insiders at OPKO Health own 49.7% of the company. Learn More about insider trades at OPKO Health.

Information on this page was last updated on 3/28/2025.

Steven D. Rubin Insider Trading History at OPKO Health

See Full Table

Steven D. Rubin Buying and Selling Activity at OPKO Health

This chart shows Steven D Rubin's buying and selling at OPKO Health by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10k-$5k$0$5k$10kTotal Insider BuyingTotal Insider Selling

OPKO Health Company Overview

OPKO Health logo
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
Read More

Today's Range

Now: $1.66
Low: $1.65
High: $1.69

50 Day Range

MA: $1.68
Low: $1.47
High: $1.94

2 Week Range

Now: $1.66
Low: $1.15
High: $2.04

Volume

3,172,415 shs

Average Volume

4,117,539 shs

Market Capitalization

$1.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7